Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells
Semantic Scholar uses AI to extract papers important to this topic.
Purpose: This study reports a phase I immunotherapy trial in 23 women with metastatic breast cancer consisting of eight infusions… Expand Purpose: This study reports a phase I immunotherapy trial in 23 women with metastatic breast cancer consisting of eight infusions… Expand Targeting HER2 overexpressed breast cancer cells with anti‑HER2 monoclonal antibodies inhibits tumor growth. Here we investigated… Expand Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA
Background: Anti-CD3 x anti-HER2Bi bispecific antibody… Expand 3075 Background: Anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) retargeting transforms activated T cells (ATC) into non… Expand A pilot phase I clinical trial involving 15 infusions of anti-CD3 × anti-CD20 bispecific Ab (CD20Bi)-armed anti-CD3-activated T… Expand 3073 Background: : Despite improvements in the treatment of metastatic breast cancer (MBC), there are no curative treatment… Expand BackgroundMyeloid-derived suppressor cells (MDSCs) are one of the major components of the immune-suppressive network, play key… Expand Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and… Expand 2548 Background: Nontoxic immunologic targeting strategies for the treatment of metastatic breast cancer (MBC) are needed. Anti… Expand